Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

What is claimed is:

1. (currently amended) A compound of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof;



(1)

wherein

R^1 and R^2 are independently hydrogen, F, CF_3, C_{1-3}alkyl, or R^1 and R^2 may together with the carbon atom to which they are attached form a 3 to 6-membered ~~cycloakyl~~ cycloalkyl ring;

R^4 and R^5 are independently hydrogen, C_{1-6}alkyl, perfluoroC_{1-6}alkyl, -OC_{1-3}alkyl, perfluoroOC_{1-6}alkyl, halogen, or cyano;

R^7 and R^8 are independently H, F, CF_3, or C_{1-3}alkyl, and the carbon to which R^7 and R^8 are bonded is attached to the benzene ring either meta or para to the depicted oxygen;

n is 1 or 2;

y is 1 or 2;

R^6 is phenyl or a 5- or 6-membered heteroaryl group, where the phenyl or heteroaryl group is optionally substituted with 1, 2, or 3 moieties selected from the group consisting of C_{1-6}alkyl, halogen, perfluoroC_{1-3}alkyl, OC_{1-3}alkyl, perfluoroOC_{1-3}alkyl, SC_{1-3}alkyl, SO_2C_{1-3}alkyl, SO_2C_{1-3}perfluoroalkyl, SOC_{1-3}perfluoroalkyl, SOC_{1-3}alkyl, perfluoroSC_{1-3}alkyl, CN, phenyl (optionally substituted with one or two groups selected from halogen, C_{1-3}alkyl, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), and 5- or 6-membered heteroaryl (optionally substituted with one group selected from C_{1-3}alkyl, C_{3-6}cycloalkyl, perfluoroC_{1-3}alkyl, NHC_{1-3}alkyl, and $N(C_{1-3}alkyl)_2$); and

R^3 is a 5- or 6-membered heteroaryl group optionally substituted by 1 or 2 moieties selected from the group consisting of halogen, C_{1-6}alkyl, perfluoroC_{1-}

$_6$alkyl, OC_{1-3}alkyl, phenyl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, OperfluoroC_{1-3}alkyl, and perfluoroC_{1-3}alkyl), 5- or 6-membered heteroaryl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), hydroxyC_{1-3}alkyl, C_{3-7}cycloalkyl, cyanoC_{1-3}alkyl, acetyl, nitro, $N(CH_3)_2$, NHR^{21} (where R^{21} is C_{1-3}alkyl, $-C(O)C_{1-3}$alkyl, $-C(O)OC_{1-3}$alkyl, or SO_2CH_3), piperidin-4-yl (substituted at nitrogen with a moiety selected from C_{1-5}alkyl, benzyl, acetyl, $C(O)OC_{1-5}$alkyl, C(O)Obenzyl, $C(O)NH_2$, $C(O)NHC_{1-3}$alkyl, SO_2CH_3), 4-(4-fluorophenyl)piperazin-1-ylmethyl, morpholin-4-ylmethyl, tetrahydrofuran-3-yl, or two adjacent carbon atoms in the heteroaryl could be substituted to form a benzene ring thus forming a fused bicycle and wherein the resulting benzene ring is optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, and perfluoroC_{1-3}alkyl.

2. (original) A compound of Claim 1 wherein R^1 and R^2 are independently hydrogen or C_{1-3}alkyl.

3. (previously presented) A compound according to Claim 1 wherein R^1 and R^2 are both hydrogen or both methyl.

4. (previously presented) A compound according to Claim 2 wherein R^4 and R^5 are independently hydrogen, C_{1-3}alkyl, perfluoroC_{1-3}alkyl, $-OC_{1-3}$alkyl, perfluoroOC_{1-3}alkyl, halogen, or cyano.

5. (previously presented) A compound according to Claim 4 wherein at least one of R^4 and R^5 are hydrogen

6. (previously presented) A compound according to Claim 5 wherein one of R^4 and R^5 is hydrogen and the other is not.

7. (original) A compound according to Claim 6 wherein the one of R^4 and R^5 that is not hydrogen is ortho to the depicted oxygen.

8. (previously presented) A compound according to Claim 5 wherein R^7 and R^8 are independently hydrogen or methyl.

9. (previously presented) A compound according to Claim 5 wherein R^7 and R^8 are both hydrogen or both methyl.

10. (previously presented) A compound according to Claim 9 wherein y is 1.

11. (previously presented) A compound according to Claim 10 wherein R^6 is phenyl optionally substituted with 1 or 2 moieties selected from the group consisting of F, Cl, CF_3, OCF_3, 5-membered nitrogen-containing heteroaryl (optionally substituted with one group selected from C_{1-3}alkyl, C_{3-6}cycloalkyl, perfluoroC_{1-3}alkyl, NHC_{1-3}alkyl, and $N(C_{1-3}alkyl)_2$).

12. (previously presented) A compound according to any Claim 11 wherein R^3 is selected from the group consisting of pyrimidine, pyridine, pyridazine, pyrazine, 1,2,4-oxadiazole, oxazole, and thiazole; and is optionally substituted by a moiety selected from the group consisting of halogen, C_{1-6}alkyl, perfluoroC_{1-6}alkyl, phenyl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), 5- or 6-membered heteroaryl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), hydroxyC_{1-3}alkyl, and C_{3-7}cycloalkyl, or R^3 may be substituted to form a fused bicycle selected from benzoxazole and benzothiazole.

13. (previously presented) A compound according to Claim 12 wherein R^3 is a pyrimidine or a pyridine; and is optionally substituted by a moiety selected from the group consisting of halogen, C_{1-6}alkyl, perfluoroC_{1-6}alkyl, phenyl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), 5- or 6-membered heteroaryl, hydroxyC_{1-3}alkyl, and C_{3-7}cycloalkyl.

14. (original) A compound according to Claim 1 selected from the group consisting of:

2-(4-{2-[[2,4-Bis(trifluoromethyl)benzyl](5-ethylpyrimidin-2-yl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)-2-methoxyphenoxy]-2-methylpropanoic acid;

2-[2-Cyano-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[3-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-fluoro-2-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-(4-{2-[(4-chlorobenzyl)(5-ethylpyrimidin-2-yl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

2-[4-(2-{(5-ethylpyrimidin-2-yl)[3-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-(4-{2-[(5-Ethylpyrimidin-2-yl)(4-fluorobenzyl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]acetic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(5-isopropyl-1,2,4-oxadiazol-3-yl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]acetic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)-2-propylphenoxy]acetic acid;

5-Ethyl-*N*-{2-[3-propyl-4-(2*H*-tetraazol-5-ylmethoxy)phenyl]ethyl}-*N*-[4-(trifluoromethoxy)benzyl]pyrimidin-2-amine;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]acetic acid;

5-ethyl-*N*-{2-methyl-2-[4-(2*H*-tetraazol-5-ylmethoxy)phenyl]propyl}-*N*-[4-(trifluoromethoxy)benzyl]pyrimidin-2-amine;

[2-Chloro-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]acetic acid;

2-[2-Chloro-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)-2-propylphenoxy]-2-methylpropanoic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)-2-propylphenoxy]acetic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)-2-methylphenoxy]-2-methylpropanoic acid;

2-[2-Chloro-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)-2-(trifluoromethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)-2-methylphenoxy]acetic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)-2-fluorophenoxy]acetic acid;

[2-Chloro-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]acetic acid;

2-[4-(2-{(5-Ethylpyridin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Isopropylpyridin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Isopropylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-Methyl-2-[4-(2-{[5-(2,2,2-trifluoroethyl)pyridin-2-yl][4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]propanoic acid;

2-[4-(2-{[5-(Hydroxymethyl)pyridin-2-yl][4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(3-{(5-Isopropylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino}propyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{[4-(2-Chlorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{[4-(3,4-Difluorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

and pharmaceutically acceptable salts, solvates, acid isosteres, and hydrolyzable esters thereof.

15. (original) A compound according to Claim 1 selected from the group consisting of: 2-[4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid, 2-[4-(2-{[4-(2-Chlorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid, 2-[4-(2-{[4-(3,4-Difluorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid, and pharmaceutically acceptable salts, solvates, acid isosteres, and hydrolyzable esters thereof.

16. (original) A compound of according to Claim 1 wherein R^1 and R^2 are both hydrogen or both methyl; at least one of R^4 and R^5 are hydrogen; R^7 and R^8 are both hydrogen or both methyl; y is 1; R^6 is phenyl optionally substituted with 1 or 2 moieties selected from the group consisting of F, Cl, CF_3, OCF_3, 5-membered nitrogen-containing heteroaryl (optionally substituted with one group selected from C_{1-3}alkyl, C_{3-6}cycloalkyl, perfluoroC_{1-3}alkyl, NHC_{1-3}alkyl, and $N(C_{1-3}alkyl)_2$); and R^3 is a thiazole, a pyrimidine, or a pyridine and is optionally substituted by a moiety selected from the group consisting of halogen, C_{1-6}alkyl, perfluoroC_{1-6}alkyl, phenyl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), 5- or 6-membered heteroaryl, hydroxyC_{1-3}alkyl, and C_{3-7}cycloalkyl.

17. (previously presented) A compound according to Claim 1 wherein the compound is a hPPAR agonist.

Claims 18-20 are deleted.

21. (previously presented) A pharmaceutical composition comprising a compound according to Claim 1.

Claims 22 and 23 are deleted.